We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of a Switch to MK-1439A in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (DRIVE-SHIFT)

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02397096
First Posted: March 24, 2015
Last Update Posted: September 29, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
  Purpose
The study will evaluate the safety and efficacy of a switch to MK-1439A (MK-1439 [doravirine] plus lamivudine and tenofovir disoproxil fumarate) in HIV-1-infected participants virologically suppressed on a protocol-specified antiretroviral regimen. The primary hypothesis is that a switch to MK-1439A will be non-inferior to continuation of the regimen at Screening for 24 weeks, as assessed by the proportion of participants maintaining HIV-1 ribonucleic acid (RNA) <50 copies/mL. The Base Study will last up to 50 weeks. An optional Extension Study will evaluate long-term efficacy and safety of the switch to MK-1439A for an additional 2 years.

Condition Intervention Phase
HIV-1 Infection Drug: MK-1439A Drug: Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor Drug: Baseline regimen of cobicistat-boosted elvitegravir Drug: Baseline regimen of a non-nucleoside reverse transcriptase inhibitor Drug: Baseline regimen of two nucleoside reverse transcriptase inhibitors Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Percentage of Participants Maintaining HIV-1 RNA <50 Copies/mL: Primary Analysis [ Time Frame: Immediate Switch to MK-1439A arm: Week 48; Delayed Switch to MK-1439A arm: Week 24 ]

Secondary Outcome Measures:
  • Change from Baseline in Fasting Low-density Lipoprotein Cholesterol (LDL-C) [ Time Frame: Both arms: Baseline and Week 24 ]
  • Change from Baseline in Fasting Non-high-density Lipoprotein Cholesterol (non-HDL-C) [ Time Frame: Both arms: Baseline and Week 24 ]
  • Percentage of Participants Maintaining HIV-1 RNA <50 Copies/mL [ Time Frame: Both arms: Week 24 ]
  • Change from Baseline in Cluster of Differentiation (CD4) Cell Counts [ Time Frame: Immediate Switch to MK-1439A arm: Baseline and Week 48; Both arms: Baseline and Week 24 ]
  • Percentage of Participants Maintaining HIV-1 RNA <40 Copies/mL [ Time Frame: Immediate Switch to MK-1439A arm: Week 48; Both arms: Week 24 ]
  • Percentage of Participants with HIV-1 RNA >=50 Copies/mL [ Time Frame: Immediate Switch to MK-1439A arm: Week 48; Delayed Switch to MK-1439A arm: Week 24 ]
  • Percentage of Participants Maintaining HIV-1 RNA <50 Copies/mL: Secondary Analysis [ Time Frame: Immediate Switch to MK-1439A arm: Week 48; Both arms: Week 24 ]

Estimated Enrollment: 660
Actual Study Start Date: June 9, 2015
Estimated Study Completion Date: March 30, 2020
Estimated Primary Completion Date: March 30, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Immediate Switch to MK-1439A
Participants receiving continuous antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or a NNRTI (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2 NRTIs for >=6 months with undetectable HIV-1 RNA will switch on Day 1 to MK-1439A single tablet by mouth once daily for 48 weeks in the Base Study and, optionally, for an additional 2 years in the Study Extension
Drug: MK-1439A
Single tablet containing MK-1439 (doravirine) 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg
Drug: Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor
Baseline regimen of antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) administered according to the product circular
Drug: Baseline regimen of cobicistat-boosted elvitegravir
Baseline regimen of antiretroviral therapy with cobicistat-boosted elvitegravir administered according to the product circular
Drug: Baseline regimen of a non-nucleoside reverse transcriptase inhibitor
Baseline regimen of antiretroviral therapy with a NNRTI (efavirenz, nevirapine, or rilpivirine) administered according to the product circular
Drug: Baseline regimen of two nucleoside reverse transcriptase inhibitors
Baseline regimen of antiretroviral therapy with two NRTIs administered according to the product circular
Active Comparator: Delayed Switch to MK-1439A
Participants receiving continuous antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or a NNRTI (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2 NRTIs for >=6 months with undetectable HIV-1 RNA will continue on this therapy until Week 24, at which time they will switch to MK-1439A single tablet by mouth once daily for 24 weeks in the Base Study and, optionally, for an additional 2 years in the Study Extension
Drug: MK-1439A
Single tablet containing MK-1439 (doravirine) 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg
Drug: Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor
Baseline regimen of antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) administered according to the product circular
Drug: Baseline regimen of cobicistat-boosted elvitegravir
Baseline regimen of antiretroviral therapy with cobicistat-boosted elvitegravir administered according to the product circular
Drug: Baseline regimen of a non-nucleoside reverse transcriptase inhibitor
Baseline regimen of antiretroviral therapy with a NNRTI (efavirenz, nevirapine, or rilpivirine) administered according to the product circular
Drug: Baseline regimen of two nucleoside reverse transcriptase inhibitors
Baseline regimen of antiretroviral therapy with two NRTIs administered according to the product circular

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Receiving antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or a NNRTI (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2 NRTIs (and no other antiretroviral therapy) continuously for >= 6 months
  • Receiving first or second retroviral regimen (participants receiving a NNRTI at Screening must be on their first retroviral regimen)
  • No history of using an experimental NNRTI
  • Not receiving lipid lowering therapy or on a stable dose of lipid lowering therapy at the time of enrollment
  • Male or female participant not of reproductive potential or, if of reproductive potential, agrees to avoid becoming pregnant or impregnating a partner while receiving study drug and for 14 days after the last dose of study drug by complying with one of the following: 1) practice abstinence from heterosexual activity, or 2) use acceptable contraception during heterosexual activity
  • For inclusion in the Extension Study (optional): completed the Week 48 visit; considered to have derived benefit from study participation up to Week 48; considered to be a clinically appropriate candidate for an additional 2 years treatment with study drug

Exclusion Criteria:

  • Uses recreational or illicit drugs or has a recent history of drug or alcohol abuse or dependence
  • Received treatment for a viral infection other than HIV-1, such as hepatitis B, with an agent that is active against HIV-1 such as adefovir, emtricitabine, lamivudine, or tenofovir
  • Has documented or known resistance to study drugs including MK-1439, lamivudine, and/or tenofovir
  • Participated in a study with an investigational compound or device within 30 days or anticipates doing so during the course of this study
  • Used systemic immunosuppressive therapy or immune modulators within 30 days or anticipates needing them during the course of this study (short courses of corticosteroids will be allowed)
  • Current, active diagnosis of acute hepatitis due to any cause (participants with chronic hepatitis B and C may enter the study as long as they fulfill all entry criteria, have stable liver function tests, and have no significant impairment of hepatic function)
  • Has evidence of decompensated liver disease or has liver cirrhosis and a Child-Pugh Class C score or Pugh-Turcotte score >9
  • Pregnant, breastfeeding, or expecting to conceive at any time during the study
  • Female and is expecting to donate eggs or male and is expecting to donate sperm during the study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02397096


Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Director Merck Sharp & Dohme Corp.
  More Information

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT02397096     History of Changes
Other Study ID Numbers: 1439A-024
2014-005550-18 ( EudraCT Number )
First Submitted: March 18, 2015
First Posted: March 24, 2015
Last Update Posted: September 29, 2017
Last Verified: September 2017

Additional relevant MeSH terms:
Ritonavir
Lopinavir
Darunavir
Atazanavir Sulfate
HIV Protease Inhibitors
Cobicistat
Nevirapine
Rilpivirine
Efavirenz
Protease Inhibitors
Reverse Transcriptase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Nucleic Acid Synthesis Inhibitors
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 CYP2C19 Inhibitors
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 Enzyme Inducers
Cytochrome P-450 CYP3A Inducers